---
figid: PMC5731654__nihms900132f2
figlink: /pmc/articles/PMC5731654/figure/F2/
number: F2
caption: Overview of impact of BRAFi on T cell response to melanomas. A) Summary of
  MAPK signaling pathway and downstream effects on MITF and melanocyte differentiation
  antigen (MDA) expression. Constitutive BRAF signaling caused by BRAFV600E results
  in inhibition of MITF and downstream MDA expression whereas BRAFi rescues MITF and
  subsequent MDA expression. B) Overview of the immunosuppressive microenvironment
  in BRAF-mutant melanoma and of the immune-based antitumor effect after initiation
  of a BRAFi including an increase in T cells, melanoma cell death, cytokines, perforin,
  granzyme B, MDA, PD-1, PD-L1 and a decrease in immunosuppressive cytokines.
pmcid: PMC5731654
papertitle: RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced
  Anti-Tumor Immunity in Melanoma.
reftext: Alexandre Reuben, et al. J Pigment Disord. 2014 Nov;1(5):139.
pmc_ranked_result_index: '26243'
pathway_score: 0.8223868
filename: nihms900132f2.jpg
figtitle: Impact of BRAFi on T cell response to melanomas
year: '2014'
organisms: Homo sapiens
ndex: 0d4e972e-de9c-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5731654__nihms900132f2.html
  '@type': Dataset
  description: Overview of impact of BRAFi on T cell response to melanomas. A) Summary
    of MAPK signaling pathway and downstream effects on MITF and melanocyte differentiation
    antigen (MDA) expression. Constitutive BRAF signaling caused by BRAFV600E results
    in inhibition of MITF and downstream MDA expression whereas BRAFi rescues MITF
    and subsequent MDA expression. B) Overview of the immunosuppressive microenvironment
    in BRAF-mutant melanoma and of the immune-based antitumor effect after initiation
    of a BRAFi including an increase in T cells, melanoma cell death, cytokines, perforin,
    granzyme B, MDA, PD-1, PD-L1 and a decrease in immunosuppressive cytokines.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK14
  - MAPK10
  - PMEL
  - HRAS
  - MAPK8
  - MAPK11
  - TYRP1
  - MAPK9
  - MAPK1
  - MAPK3
  - MITF
  - BRAF
  - NRAS
  - MAPK13
  - PDCD1
  - KRAS
  - MAP2K1
  - MAP2K2
  - DCT
  - CD8A
  - MAPK12
  - KIT
  - RAF1
  - CD8B
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: gp100
  symbol: gp100
  source: hgnc_alias_symbol
  hgnc_symbol: PMEL
  entrez: '6490'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: TYRP-1
  symbol: TYRP1
  source: hgnc_symbol
  hgnc_symbol: TYRP1
  entrez: '7306'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MITF
  symbol: MITF
  source: hgnc_symbol
  hgnc_symbol: MITF
  entrez: '4286'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: TYRP-2
  symbol: TYRP2
  source: hgnc_prev_symbol
  hgnc_symbol: DCT
  entrez: '1638'
- word: CD8*
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: c-Kit
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: CD8*
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC5731654__F2
redirect_from: /figures/PMC5731654__F2
figtype: Figure
---
